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Abstract
Menopause transition is recognized as a vulnerable period in women life to develop or 
aggravate symptoms of psychiatric disorders. Several treatments including antidepressants 
and hormonal restitution with estrogens have been suggested to ameliorate the symptoms. 
Also, in this period of life is frequent the use of other drugs to treat is also frequent the use 
of other drugs to treat comorbid pathologies that might even increase the risk of drug-drug 
interactions. Literature reports that some phytochemicals with estrogenic activity have ben-
eficial effects during menopausal transition without collateral events. This chapter shows 
evidence about the use of phytoestrogens as an alternative therapy for the treatment of 
some psychiatric symptoms associated with the menopausal transition. Data derived from 
preclinical research related to the use of classical phytoestrogens (isoflavones), considering 
the beneficial effects, as well as adverse events, are discussed. Also, the use of polyphenols 
and organosulfurate compounds as an alternative for the treatment of anxiety- and depres-
sive-like behavior as well as fibromyalgia is included. A narrative review was conducted 
using bibliography reporting the use of isoflavones (genistein, daidzein, equol), coumes-
tans or lignans for the reduction of depressive-like or anxiety-like behavior. Furthermore, it 
is described if the use of this compounds impact in other signs of menopause, i.e. vasomotor 
and osteoporosis. In addition, due to the high frequency of comorbid pathologies as dia-
betes mellitus, dyslipidemia or metabolic syndrome with psychiatric disorders, the use of 
these phytochemicals is discussed.
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1. Introduction
With the increase of life expectancy, women potentially spend the last third of their lives in 
post-menopause. Most of the menopausal women suffer from a variety of symptoms such as 
hot flashes, night sweats, mood swings, insomnia, vaginal dryness and osteoporosis [1, 2]. Also, 
the menopause transition could be a vulnerable period to develop some diseases related to 
mental disorders (i.e., anxiety and depression) and chronic non-degenerative pathologies (met-
abolic diseases) in addition to menopausal symptoms [3, 4]. This situation implies that women 
that transit in this period of life could be vulnerable to develop co-morbidities leading to a com-
plex medical management due to the elevated cost and possible pharmacological interactions.
Hormone replacement therapy is considered the first line of treatment for menopause symp-
toms, mainly vasomotor and night sweats. However, many women refuse it because of their 
association with increased risk of breast cancer and are considering botanical products or 
dietary supplements as therapy because they are regarded as safer products [1, 2, 5]. For 
example, black cohosh is widely employed for hot flashes and mood disorders; others are 
compounds with estrogenic activity (phytoestrogens) as soy food products, red clover, kudzu, 
hops, licorice, rhubarb, yam and chasteberry [1].
The use of functional food and nutraceuticals became common to treat menopause symptoms 
[2]. The term “nutraceutical” combines two words—“nutrient” (a nourishing food component) 
and “pharmaceutical” (a medical drug). It is defined as “any substance that may be consid-
ered a food or part of it that provides medical or health benefits, including the prevention and 
treatment of diseases.” These products include isolated nutrients, dietary supplements and 
diets genetically engineered “designed” foods, botanical products and processed foods such 
as cereals, foods and beverages [6]. A nutraceutical is demonstrated to have a physiological 
benefit or provide protection against chronic disease [6]. On the other hand, functional food 
according to American Dietetic Association, “functional” implies that the food possesses some 
identified value leading to health benefits, including reducing the risk of adverse effects for a 
person consuming it [7].
Nutraceuticals and functional food are classified in several manners taken into account their 
content of specific food, properties (anti-cancer, positive influence on blood lipid profile, anti-
inflammatory, osteogenic or bone protective) or chemical structure [6]. Both nutraceuticals 
and functional food contain active compounds called phytochemicals that confer their prop-
erties. Phytochemicals are products of the secondary metabolism of a plant which are bio-
logically active in humans and other animal species playing a greater beneficial role in health 
more than only nutritional properties. These products are part of the defense system and 
plants’ protection [8], and in humans, they have activity in several systems such as the diges-
tive, immune, cardiovascular, endocrine and central nervous system [6, 8], among others. 
Also, phytochemicals confer organoleptic properties to vegetables and fruits [8].
Phytochemicals are classified into four groups according to their impact on health [9, 10]:
1. Terpenoids (i.e., carotenoids and phytosterols)
2. Phenols (i.e., flavonoids, phenolic acids, tannins, stilbens and curcuminoids)
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3. Organosulfurate compounds (i.e., glycosinolates and isothiocyanates)
4. Nitrogen compounds (i.e., alkaloids, betalainas, indol-glycosinolates)
The distribution of phytochemicals’ sources could be at the same time diffuse and copious as 
well as specific depending on the product, for example, carotenoids are frequently found in sev-
eral products (carrots, tomato, orange, mango, pumpkin, guava), whereeas glycosinolates are 
found only in cruciferous (broccoli, brussel sprout, cabbage, horseradish, rutabaga) [8]. The con-
centration of the phytochemical could vary depending on the morphological factors: skin, seed, 
pulp, peel, leaves, also on agronomic factors: weather, agricultural soil, technical procedure, 
physiological stress; and postharvest: maturity, processing and storage, among the others [8].
2. Phytochemicals: polyphenols
Polyphenols can be found in a large variety of food mainly of vegetable origin. They constitute 
the major group of natural compounds known (around 8000 identified) in the plant kingdom 
[11]. These compounds result of the secondary metabolism of carbon by the acetate-malonate 
and shikimate pathways. They are characterized by the presence of phenolic structures with a 
potent antioxidant activity that confers protection to plants against oxidative stress, ultravio-
let radiation and other harmful factors of the environment such as pollutants and pathogens 
[12]. There are a wide variety of polyphenols but, in general, they have been classified into 
two groups according to their chemicals properties: flavonoids and non-flavonoids (Figure 1).
Figure 1. The scheme illustrates the main polyphenols and their division. Phytoestrogens are products of the metabolism 
of polyphenols: isoflavones and coumenstans are flavonoids, whereas lignans and stilbens are non-flavonoids.
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The flavonoid group includes compounds whose structure contains the flavan nucleus 
(diphenyl propane; C:15: C3, C6, C3), such as anthocyanidins, proanthocyanidins, catechins, 
flavones, flavonols, flavanones, isoflavones and coumestans (Figure 1). The non-flavonoids 
group includes phenolic acids, phenolic amides and other polyphenols, such as tannins, lig-
nans and stilbene compounds (Figure 1). Polyphenols, flavonoids and nonflavonoids have 
biological importance and are considered as nutraceuticals, not only for their antioxidant 
effect but also for their beneficial effects on health such as cardiovascular, diabetes and neuro-
degenerative protection, cancer prevention and anti-infection effect [11].
Recently, it has been determined that some polyphenols, especially isoflavones, flavonols, 
anthocyanidins, lignans, stilbenes and coumestans, have estrogenic activities, for which they 
have been denominated as phytoestrogens.
3. Phytoestrogens
Phytoestrogens are non-steroidal compounds that have a unique similarity in molecular 
weight and the arrangement of aromatic rings with hydroxyl groups to the cyclopentanoper-
hydrophenanthrene of 17β-estradiol (the most important endogenous estrogen; Figure 2).
Figure 2. Phytoestrogens. The figure illustrates comparatively the chemical structure of 17β-estradiol and some 
phytoestrogens. Phytoestrogens are non-steroidal compounds that have a unique similarity in molecular weight and 
the arrangement of aromatic rings with hydroxyl groups to the cyclopentanoperhydrophenanthrene of 17β-estradiol.
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The types of phytoestrogens are isoflavones, lignans, coumestans, ellagitannins and stilbens 
[13–15]. Figure 3 shows the main sources of phytoestrogens and the phytochemicals with estro-
genic properties. The primary sources of lignans are flaxseed, whole grain cereal and some 
beverages, such as coffee, tea and wine [15]. For isoflavones are legumens such as soybeans and 
peanuts,  chickpeas and kudzu, lupine, fava, alfalfa, peanuts and chickpeas [15]. In the case of 
clover alfalfa and soybean sprouts, these are sources of coumestans [13]. Ellagitannins are abun-
dant in fruits, nuts and seeds such as pomegranate, black raspberries, strawberries, walnuts and 
almonds [16]. The main source of stilbens such as revestratrol is the red wine and peanuts [15].
It is important to note that the beneficial actions of phytoestrogens are mostly given by the 
estrogenic/anti-estrogenic effect dependent on the resultant concentration of the metabolism 
Figure 3. Phytoestrogens and their main food or beverage source. Ellagitannins, lignans and isoflavones require of 
microbiota biotransformation to release an active compound (urolithins A and B, enteronolactone or Equol, respectively) 
that produces their estrogen-like effects on different tissues. In contrast, stilbens and coumestans production appears to 
be independent of microbiota.
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of phytoestrogens. It is known that phytoestrogens are mostly as glycosides and that only 
the aglycone fraction is bio-available to produce biological effects [17]. Some phytoestrogens, 
such as isoflavones, ellagitannins and lignans, require the action of gut bacterial enzymes 
to produce equol, urolithins and enterolignans, respectively [16, 18, 19]. These subprod-
ucts have more bioavailability and have more estrogenic/anti-estrogenic and anti-oxidant, 
anti-inflammatory and anti-proliferative activity than their precursors [20]. Furthermore, it 
is proposed that the biotransformation of isoflavones, ellagitannins and lignans by intesti-
nal microbiota is essential in protection against menopausal symptoms. Also against certain 
chronic diseases, such as cancer, cardiovascular disease and osteoporosis [15], suggesting 
that the main discrepancies between a successful treatment versus lack of effect could be 
explained by the low bioavailability of phytoestrogens [21].
In this line, several reports indicate that coumestans—coumestrol and methoxycoumestrol—
show estrogenic activity; the most active compound of isoflavones is daidzein intestinal-
derived metabolite equol. However, other products such as genistein, daidzein, glycitein 
and their respective β-glycosides of genistein and daidzein possess estrogenic activity [13]. 
Ellagitannins are metabolized to urolithin A and B which showed estrogenic activity [15, 22]. 
Also, lignans are metabolized in the gut to produce the most estrogenic enterolignans, entero-
diol and enterolactone [18].
On the other hand, the chemical similarity between 17β-estradiol and phytoestrogens confers 
the capability to interact with estrogen receptors (ERs). They produce effects through genomic 
actions with ERs alpha and beta (α, β) or non-genomic actions via membrane G-protein recep-
tors (GPER) such as GPR30 and mERα and mERβ [23]. These receptors differ in tissue dis-
tribution, ligand selectivity and transcriptional processes and, therefore, also differ in their 
physiological effects on its activation [24–26]. These interactions between phytoestrogens and 
ERs results on estrogenic and/or anti-estrogenic effects, so that phytoestrogens are considered 
as selective estrogen receptor modulators (SERMs) [27–29].
Several in vitro assays suggest that phytoestrogens, especially isoflavones, have a signifi-
cant preference for ERβ rather than for ERα (8- to 40-fold) [30–33]. Some authors explain this 
preference through steric interaction and through the difference in the attractive potential 
of hydrogen bonds between the ERs and phytoestrogens, which is higher in ERβ [34]. It is 
thought, that in some way the beneficial actions of the estrogenic compounds are related to 
the ERβ, in part because the activation of ERβ has been associated with the anti-proliferative 
actions of phytoestrogens [35–37].
GPER activation by phytoestrogens has been relatedto cardiovascular, liver enzymatic and 
neuroprotective actions [35, 38–40]. Some research groups have proposed that the GPR30 also 
take part in the endocrine disrupting action of phytoestrogens [41]. Phytoestrogens also show 
high potency in non-genomic responses. Therefore, it is proposed that their binding affinities 
could be higher for mERs [42] albeit the involvement of these receptors in the phytoestrogens 
actions is less explored.
As it can be seen phytoestrogens also possess a complex mechanism of actions to exert their prop-
erties, for example, the rapid neuroprotective activity of resveratrol against cerebral ischemia 
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is mediated by ERα and ERβ, and it is blocked by the estrogen receptor antagonist ICI 182 
780 [36]. In contrast, Daidzein protects from excitotoxicity induced by glutamate via ERβ and 
GPR30 [35].
4. Alternative to the hormone replacement therapy on menopause
4.1. Clinical studies
During menopause, symptoms such as body weight changes, vaginal dryness, hot flushes, 
sweating, sleep disturbances and loss of bone density may occur, also cognitive distur-
bance, mood changes and depression episodes that lead women to a poor quality of life [43]. 
Symptoms could vary in intensity and in some women, they could be debilitating, particu-
larly for those women who have a previous experience of depression and anxiety in addition 
to vasomotor, insomnia, weight gain and stressful life events [44].
Hormone replacement therapy (HRT) is the first line of treatment followed by the treatment 
with selective serotonergic reuptake inhibitors antidepressants [2, 45]. Despite their benefits 
and efficacy for reducing most of the discomforts of menopausal women, the long-term use of 
HRT has been extremely controversial because of the adverse events associated. These include 
an increase in the risk of stroke and venous thromboembolism, an increase in endometrial, 
ovarian and breast cancer, in addition to the regular side effects of HRT such as headaches, 
weight changes, nausea and pruritus, among others. On the other hand, it has been reported 
that the adverse effects depend on several factors. Randomized trials have shown that the risk 
of presenting adverse effects is mainly given in women older than 60 years old, women dur-
ing postmenopausal and after 5 years of the continued usage of the HRT.
Other therapies including non-pharmacological interventions have been recommended such 
as psychotherapy to address the psychological symptoms, acupuncture, physical exercise, 
nutritional interventions, botanical products and folk medicine, among others [44, 46].
Nevertheless, it is increasingly common for women to prefer an alternative therapy based on 
the intake of therapeutic compounds of natural origin instead. The alternative therapy can be 
based either on the consumption of food that may provide health benefits beyond nutrition 
(functional food) or on the administration of compounds isolated from food (nutraceuticals) 
with the same purpose. In this sense, phytochemicals as phytoestrogens have received much 
attention because of their particular health benefits which have allowed the emergence of an 
alternative to HRT.
Most of the therapies used to treat menopausal symptoms have been focusedon alleviating 
vasomotor and night sweat complaints. One of the most popular therapies is based in the use 
of black cohosh [33], Valerian and St John’s wort [33, 46] due to the lack of estrogenic effects. 
Briefly, black cohosh (Cimicifuga racemosa L. Synonym Actearacemosa L.) has been used for 
centuries by native Americans for a variety of women’s health issues [33]. It is agreed that 
black cohosh is not estrogenic and its mechanism of action may involve modulation of the 
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serotonergic system in a similar manner than antidepressants [1]. This botanical product has 
been tested in several trials given contradictory results. Indeed, the main effects appear to be 
related to vasomotor and emotional symptoms [33, 47]. For example, in a multicenter ran-
domized, double-blind, placebo-controlled, parallel group trial, the effect of several doses 
of black cohosh was tested taking into consideration as a primary outcome the difference in 
menopausal symptoms (vasomotor, psychological and somatic), assessed by the Kupperman 
Menopausal Index between baseline and week 12. Secondary efficacy variables were patients’ 
self-assessments of General Quality of Life (QoL), responder rates and safety. Compared to 
placebo, patients receiving black cohosh showed a significant reduction in the severity of 
vasomotor and psychological symptoms and improved general QoL in a dose-dependent 
manner from baseline to endpoint [47]. In contrast, recent clinical trials have reported adverse 
effects of black cohosh with no significant difference from placebo for relief of hot flashes or 
improving QoL in Thai women [48].
The phytoestrogens mostly used with documented effects are isoflavones. These compounds 
obtained from different sources have been used primarily to alleviate vasomotor symptoms, 
but the results appear not to be consistent on mood complaints. For example, in a metaanalysis 
(43 randomised controlled trials with 4364 participants) that evaluate the effect of isoflavones 
from soy and red clover in the treatment of hot flushes and insomnia associated with meno-
pause, no significant difference overall was reported in the incidence of hot flushes between 
participants taking Promensil (a red clover extract that contains isoflavone biochanin A and 
formononetin) and those given placebo. In this review, four trials suggested that extracts with 
high levels (>30 mg/d) of genistein consistently reduced the frequency of hot flushes. Some of 
these trials found that phytoestrogen treatments alleviated the frequency and severity of hot 
flushes and night sweats when compared with placebo, but many trials were small and were 
determined to be at high risk of bias. A strong placebo effect was noted in most trials, with a 
reduction in frequency ranging from 1 to 59% with placebo. Discrepant results could be related 
to the amount of isoflavone in the active treatment arm, the severity of vasomotor symptoms 
or trial quality factors [49].
Other studies tested the effect of red clover and also found controversial results. For example, 
a trial of 72 women randomly divided between placebo and 40 mg dried red clover daily for 12 
weeks showed a significant reduction in menopausal symptoms as measured by the Menopause 
Rating Scale [50]. In contrast, other clinical trials have not shown a significant difference from 
placebo, particularly for hot flashes relief [5]. Interestingly, red clover has proestrogens, bio-
channin A and formonetin, which are metabolized by CYP 450 in the gut and liver in genistein 
and daidzein [51], suggesting more bioavailability compared with soy products. This could be a 
reason why the use of red clover appears to be more effective than soy in the clinical trials [52].
Kudzu (Pueraria lobata Willd.) Ohwi (Fabaceae) is a traditional Chinese medicine for the treat-
ment of the symptoms of menopause [1]; the major isoflavone in kudzu is puerarin, which is 
metabolized to daidzein by gut microbiota. Clinical trials with kudzu reported no significant 
changes in the menopausal complaints compared with control group [53].
Other compounds with estrogenic activity that differ from isoflavones have been tested, for 
example Hop (Humulus lupulus L.) (Cannabaceae). Hop extracts are in some dietary supplements 
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used for managing menopausal symptoms [54]. The most potent phytoestrogen in hops is the 
ERα-selective agonist 8-prenylnaringenin (8-PN), which is 100-fold more potent than the ERβ-
selective isoflavones genistein and daidzein [33]. Clinical trials suggest positive results of 8-PN 
in reducing the symptoms of menopause [54] however due to their high affinity to ERα; it is 
important to evaluate the safety on the endometrium and other hormone-sensitive tissues [33].
Rhubard (Rheum rhaponticum L.) (Polygonaceae). Rhubard is a plant used for menopausal 
symptoms relief in Germany [54]. The extract from roots of rhubard mainly consists of rha-
ponticin and desoxyrhaponticin, which are converted to the resveratrol-like aglycones rha-
pontigenin and desoxyrhapontigenin by the microbiome. Rhapontigenin is more active than 
desoxyrhapontigenin, and it is suggested that P
450
-catalyzed O-demethylation giving the res-
veratrol-catechol piceatannol might be responsible for its estrogenic activity [14, 55]. Clinical 
trials show that the rhubarb extract was effective and successfully decreased the Menopause 
Rating Scale and increased QoL [56–58].
Flaxseed (Linum usitatissimum L.) (Linaceae). Flaxseed is a primary source of lignans that are 
metabolized by the microbiota into the phytoestrogens, enterolactone and enterodiol [18]. In 
a randomized placebo-controlled clinical trial (90 women, 1 g/day flaxseed extract), modest 
but significant effects were observed in self-reporting relief of menopausal symptoms [59]. 
Nevertheless, a meta-analysis that included randomized clinical trials examining the efficacy 
of flaxseed for menopausal symptoms, concluded that there is little evidence to support the 
use of this dietary supplement for menopause or bone health [60].
Another product most employed in South America is maca (Lepidium meyenii Walp.) 
(Brassicaceae), it is used for hormonal balance, especially for menopausal symptoms [54]. 
Albeit the active phytoestrogen has not been detected, the extract of maca showed estrogenic 
effect increasing proliferation in MCF-7 cells. A systematic review of clinical trials concluded 
that evidence of the effectiveness of maca for the relief of menopausal symptoms was limited. 
However, because of the sample size, the number of trials and the quality of the trials, it is not 
pertinent to establish definite conclusions about the efficacy and safety [61].
Recently, in a placebo-controlled trial, the efficacy of resveratrol and equol supplementation 
was tested on menopausal women aged 50–55 years who received 200 mg of fermented soy 
containing 10 mg of equol and 25 mg of resveratrol (1 tablet/day) during 12 weeks. The pri-
mary outcome was the change in score on the Menopause Rating Scale, used to evaluate the 
severity of age-/menopause-related complaints. Additional outcomes included the Hamilton 
Rating Scale for Depression (HAM-D) and Nottingham Health Profile (NHP), which were 
used specifically to assess sleep quality. Treatment was effective to reduce Menopause Rating 
Scale and HAM-D scores, importantly on work and activity items and with a slight effect on 
anxiety-related items [62].
According to the results of meta-analyses, there is no enough clinical evidence that supports 
the use of phytoestrogens as HRT to alleviate all symptoms of menopause. Albeit an improve-
ment in the quality of life is reported. An important issue to consider is the use of standardized 
phytoestrogens and ethnicity of the women included in the studies since these factors could 
be crucial to obtain a positive result for those phytoestrogens that require specific microbiota 
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biotransformation. Promising results are derived from isoflavones and their precursor 
because of non-adverse effects reported. However, in all cases, more controlled-clinical trials 
using large samples with women of different ethnicities are required.
4.2. Preclinical studies
In contrast to the clinical studies where the phytoestrogens were evaluated mainly to prevent 
or alleviate the vasomotor symptoms, in preclinical data, studies were focused on the evalu-
ation of anxious and depressive-like behaviors. Some of the phytoestrogens are considered 
selective estrogens receptors modulators and are derived from the metabolism of isoflavones. 
Importantly, most of them showed an affinity for ERβ, characteristic that may explain their 
effect partially as an antidepressant [63]. However, others showed an affinity for ERα or mem-
brane receptors, making the study of their mechanism of action complex.
Early studies evaluated the effect of dietary phytoestrogens as anxiolytic-like agents [64]. The 
authors tested the effect of phytoestrogens in the offspring of mothers fed with a dietary soy 
derived phytoestrogens (600 µg/g) and found a reduction in the anxiety behavior in those ani-
mals that were maintained with soy diet when adulthood. Rodents fed with soy also showed 
less body weight [64]. Unfortunately, in this paper, the authors did not indicate the phytoes-
trogens bounded with the behavioral effect but reported high levels of equol in plasma, the 
more active metabolite of isoflavones found in the soy [14].
After that, several doses of a diet rich in phytoestrogens (200 or 600 ppm of phytoestrogens in 
diet) and equol injections (5 mg/kg) were evaluated in the forced swimming test in rats under 
different endocrine conditions: intact, ovariectomized and aged rats with natural ovarian fail-
ure [65]. Interestingly, the latter group resembles an animal model of “natural menopause” 
because rats are acyclic, and it is the only report, as far as we know, that evaluate the effect of 
the isoflavones under this condition. Authors showed that soy diet rich in phytoestrogens and 
equol produced antidepressant-like effects at the same time that induces a reduction of body 
weight and white adipose tissue in all endocrine conditions. After the soy-rich diet, high plas-
matic levels of genistein, daidzein and equol were detected in those animals that received the 
highest dose [65]. Unfortunately, the authors did not evaluate anxiety-like behaviors.
In contrast, no effect or anxiogenic effect was reported after a rich isoflavone diet administra-
tion [66, 67]. It is important to mention that these data were generated in male rats instead 
of female rats where more information is needed. Briefly, when a soy-rich diet containing 
150 µg/g total isoflavones (daidzein and genistein) was dispensed to young male Lister rats, 
an anxiogenic effect was reported in the elevated plus-maze and social interaction test. Diet 
neither affected water intake nor the weight of rats but enhanced the corticosterone and 
vasopressin stress-response [66], suggesting an increase in sensitivity to stress. The authors 
explained the apparent discrepancy between results, i.e. Lund and Lephard [64] versus 
Hartley et al. [66] considering timing and dose used (150 µg/g versus 600 µg/g). Other dif-
ference that could be noted is the strain of rats, Long-Evans [64] versus Lister rats [66] and 
the sex of the rats. The latter is an important issue since Harley et al. [66] used intact male 
rats, and Lund and Lephard [64] used intact male and female rats finding positive results in 
anxiety in females but impaired the anxious-like state in males. Further, Patisaul et al. [67] 
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showed that the administration of a soy-rich (600 µg/g) diet to gonadally intact male rats 
produced anxiogenic effects. Furthermore, authors tested high (20 mg/kg) and low (3 mg/
kg) doses of equol and resveratrol (3 and 20 mg/kg) in two animal models of anxiety in intact 
male rats. The authors reported that these compounds did not produce any effect after 3 days 
of treatment and discussed the possibility that the endocrine condition that prevails in males 
could be a factor to explain the lack of effect [67].
Following this idea, recently it was hypothesized that the role of isoflavones in the regulation 
of anxiety and depressive-like behavior depends on the endocrine status [68]. To test this 
hypothesis, the authors evaluated the anxiolytic- and antidepressant-like effect of isoflavone-
rich diet (199.4 µg/g) in ovariectomized rats exposed, or not exposed, to estradiol replacement. 
Data showed that anxiolytic and antidepressant-like effects depend on the endocrine state 
that prevails during the treatment with isoflavones. In this case, an isoflavone diet combined 
with estradiol restitution promotes anxiety; in contrast, the same combination promoted an 
antidepressant-like effect [68]. Unfortunately, authors did not show evidence about the phy-
toestrogens that could be responsible for the observed effect.
The isoflavone genistein has been evaluated as an antidepressant and anxiolytic compound. 
This phytoestrogen also showed more affinity for ERβ than ERα [69], and recent reports also 
suggested that it binds to ERm. Rodríguez-Landa et al. [70]) assayed several doses of this com-
pound (0.25, 0.5 and 1.0 mg/kg, i.p.) after 4 days of administration in Wistar rats with 12-weeks 
after the elimination of ovaries. This model resembled a long-term period of menopause and was 
used to evaluate if genistein was able to induce anxiolytic-like effects as hormone replacement 
therapy after a long-term ovariectomy. In this study, authors showed that genistein was effective 
in reducing anxiety-like behavior in the black and white model after a long-term postovariec-
tomy. Interestingly, it has been reported that E
2
 is ineffective to produce behavioral effects after 
a long-term ovaries removal [71–73]. Therefore, the results obtained with genistein open the 
opportunity to use this compound as a restitution therapy. Furthermore, clinical and preclinical 
studies reported that genistein lacks stimulatory effects in breast and uterus [33]. Genistein also 
showed antidepressant-like effects in rats subjected to the forced swimming test. In this case, 
genistein (10 mg/kg) was administered during 14 days to ovariectomized rats and reduction of 
immobility behavior was observed. Data also indicated that genistein increased dopamine and 
restored the serotonin levels in the hippocampus at a dose of 10 mg/kg [74]. Interestingly, the 
effect of this compound was also tested after a subacute administration (i.e., three injections in 
24 hours) and no effect was observed. This result suggested a genomic mechanism of action [74].
Another compound with estrogenic properties that has been tested is coumestrol (7,12-dihy-
drocoumenstan), which is considered a SERM that shows an affinity for the ERβ [69]. This 
compound was assayed in the forced swimming test and several models of anxiety after 
systemic (10 µg/kg) and intracerebral administrations (2 µg/µl/slide) to ovariectomized rats. 
A reduction of depressive-like and anxiety-like behavior was reported after both routes of 
administration [63]. As it can be noted, coumestrol is effective as an anxiolytic or antidepres-
sant compound in ovariectomized rats; however, it is necessary to evaluate its effect in young 
intact and acyclic female rats to establish whether the effect of this compound remains even 
in the presence of ovarian secretion.
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Also, secoisolariciresinol (SECO) is a lignan type phytoestrogen mainly found in flaxseed that 
can be metabolized to enterodiol and enterolactone. This compound was administered (5, 10 
and 20 mg/kg, intragastric) during 14 days to ovariectomized mice and tested in two animal 
models for the screening of antidepressant drugs, the tail suspension test and the forced swim-
ming test. The authors reported an antidepressant-like effect of SECO in both behavioral tests. 
Furthermore, this compound restored noradrenaline brain levels and increased dopamine and 
serotonin concentrations without promoting a stimulatory effect on the uterus [75]. An impor-
tant difference in comparison to other protocols presented here is that SECO was administered 
immediately after the ovariectomy. Therefore, the restitution started before a real drop in endog-
enous estrogen levels, suggesting a model of perimenopause rather than a menopause model.
Phytoestrogens appear to promote anxiolytic and antidepressant-like actions in animal models. 
However, it can be noted that the time, the dose and endocrine state are factors that may condi-
tion the effect of these estrogenic compounds. In general, acute interventions are ineffective; 
most of the reports indicate that more than 3 days are necessary to observe an anxiolytic or anti-
depressant-like effect. For isoflavones, their effect appears to depend on the time of restitution 
and the endocrine state of rats. In this line, the fact that their anxiolytic-like effect is observed in 
ovariectomized or acyclic females but not in intact rats suggests that isoflavones are working as 
a restitution therapy and the levels of phytoestrogens that are bioavailable after diet adminis-
tration are enough to induce changes in the respective receptors like a natural estrogen.
5. Alternative sources of phytoestrogens
5.1. Punica granatum L. (Lythraceae)
Pomegranate is a fruit native of Western Asia and North Africa. However, it is now cultivated 
in most of the Mediterranean and North America region [76]. Table 1 shows the main phyto-
chemicals reported for pomegranate.
Over the last decades, pomegranate and pomegranate extracts have demonstrated to possess 
several beneficial health effects for which it is considered a functional food. Clinical and pre-
clinical studies have shown that pomegranate has anti-oxidant [77], anti-inflammatory, anti-
tumorigenic, anti-microbial [78], anti-obesity [79], anti-nociceptive [80], neuroprotective [81] and 
antidepressant-like properties [82–84]. Interestingly, most of the health benefits of pomegranate 
are attributed to its high content of polyphenols, which represents the 26–30% of the total weight 
of the fruit [85]. The main polyphenols present in the pomegranate are ellagitannins, such as puni-
calagin (α and β), and flavonoids such as anthocyanidins, catechins, flavonols and isoflavones 
[80, 86–88]. Ellagitannins are a type of hydrolyzable tannins with several hexahydroxydiphenoyl 
(HHDP) groups esterified to sugar moieties. When consumed, ellagitannins are easily hydro-
lyzed to ellagic acid in the acidic conditions of the gastric juice because of its hydrophilic nature. 
Therefore, on different portions of the small and large intestine, ellagitannins are transformed by 
bacterial metabolism to dibenzopyranone compounds called urolithins. These compounds have 
recently demonstrated to possess estrogenic activity on in-vitro assays; this particularity makes 
pomegranate an excellent source of phytoestrogens [16, 22, 78, 89]. Under this premise, some 
A Multidisciplinary Look at Menopause92
research groups have sought its therapeutic potential for the treatment of symptoms in meno-
pause. In 2012, the therapeutic effect of a 12-week schedule of pomegranate seed oil (PGS) on 
menopausal symptoms was investigated with a neutral response, i.e., PGS reduced menopausal 
symptoms, but with no significance, authors remarked the importance of evaluating the PGS for 
a longer period [90]. Furthermore, a systematic review reported the effect of pomegranate juice 
in osteoporosis, osteoarthritis, or rheumatoid arthritis. All the studies reported positive effects of 
pomegranate extract or juice on osteoporosis, osteoarthritis and rheumatoid arthritis [91].
Preclinical studies have reported that the juice of pomegranate reduced menopausal symp-
toms in animal models by inducing antidepressant-like effects and decreasing bone loss [92]. 
Part of the pomegranate Phytochemicals
Whole Ellagitannins
Anthocyanins
Anthocyanidins
Catechin
Proanthocyanidins
Seed and oil Acid derivates
Fatty acids
Triglycerides
Sterols
Terpenoids
Peel and pericarp Ellagitannins
Gallotannins
Hydroxybenzoic acids
Proanthocyanidins
Flavonols
Leaves Ellagitannins
Flavones
Flavonols
Flavone glycosides
Alkaloids
Acid hydroxybenzoic
Triterpenoids
Flavones
Phytochemicals found in several parts of pomegranate [79, 80, 86, 87].
Table 1. Phytochemicals found in Punica granatum L.
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In our laboratory, an extract of pomegranate in the elevated plus-maze for the screening of 
anxiolytic action and the forced swimming test for an antidepressant-like effect (unpublished 
results) was evaluated. This extract has a high content of ellagitannins and previously showed 
anti-inflammatory and antinociceptive properties [80] After 7 days of intraperitoneal admin-
istration, a reduction of anxiety-like behavior was detected and a lack of effect in the forced 
swimming test. The decrease of anxiety was detected at 1.0 mg/kg (see Figure 4). Importantly, 
Figure 4. Effect of several doses (0.1, 1.0, 10 mg/kg, i.p) of aqueous extract of pomegranate (Punica granatum L.) in the 
elevated plus-maze (A) and the forced swimming test (panel B) after 7 days of treatment. Pomegranate extract reduced 
the anxiety-like behavior (panel A) but lacks antidepressant-like effect (B). Data are presented as mean ± SE of 10–12 
ovariectomized rats per group. *p < 0.05 versus control group; +p < 0.05 versus 0.1 mg/kg, One-way-ANOVA followed by 
Student-Newman Keuls test. Unpublished results.
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the fact that the administration route was intraperitoneal suggests that other phytochemicals 
more than ellagitannins, which require of microbiota transformation, could be present in the 
extract. Future experiments may contribute to elucidate the phytochemical bounded in the 
anxiolytic effect of pomegranate.
5.2. Brassica oleraceae var. italica
Broccoli (Brassica oleracea var. italica Plenck) belongs to the Brassicaceae of cruciferous family 
where cabbage, brussels sprouts and radish can also be found [93]. It is native to the Anatolian 
peninsula and now is widely cultivated in other parts of the world. The phytochemical con-
tent of broccoli is shown in Table 2. As it can be seen, broccoli is also a source of important 
polyphenols, and consequently, phytoestrogens since in its composition, it can be detected 
quercetin, kaempferol, daidzein, antocyanins [93, 94], coumestans and lignans [45, 95].
Phytochemicals Unity Broccoli
β-Carotene UI 318.56
Zeaxanthin UI 22
Lutein μg 1123.76
β-Cryptoxanthin UI 0.88
Quercetin mg 2.2
Kaempferol mg 0.008
Myricetin mg 3.5288
Daidzein mg 0.0352
Anthocyanin μg 0.01
Lignans μg 0.528
Glucoiberin μmol 145.2
Glucoraphanin μmol 646.8
Progoitrin μmol 80.15
Glucoalyssin μmol 69.78
Gluconapin μmol 22.88
Glucobrassicanapin μmol 23.707
Gluconasturtiin μmol 9.52
Glucobrassicin μmol 308
Neo-glucobrassicin μmol 84.48
Chlorophyll (A) mg 0.88
Chlorophyll (B) mg 0.748
Phytochemicals of Broccoli. Data are expressed as UI, mg, µg or µmol per 98 g of dried sample [96–117].
Table 2. Phytochemicals in different parts of Brassica oleraceae.
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Broccoli is also a source of a potent anti-oxidant and anti-inflammatory compound called sul-
foraphane (1-isothiocyanato-4-methylsulfinylbutane) which is an organosulfur compound 
[118]. Several reports indicated that this compound might prevent depressive-like behavior 
induced by the inflammatory process. For example, acute sulforaphane at 3–30 mg/kg and glu-
corophanin (glucosinolate precursor of sulforaphane) in the diet were tested in male C57BL/6 
mice. In this case, it was to determine whether these compounds were able to prevent the onset 
of depression-like behavior after an induction of inflammation by lipopolysaccharide adminis-
tration [118]. In this chapter, authors also evaluate the effect of sulforaphane on brain-derived 
neurotrophic factor (BDNF) levels, synaptogenesis protein and dendritic spine density in the 
brain. The results showed that sulforaphane prevents the increase of TNF-α, IL-10 and microg-
lia activation blocking the inflammation process at the same time that decreased the depres-
sive-like behavior evaluated by two behavioral test. Interestingly, sulforaphane also reverses 
the reduction of BDNF expression and dendritic spines induced by inflammation process [118].
In another study, the effect of sulporaphane and glucorophaninwas tested on depressive-like 
behavior after repeated social defeat stress using Nrf2 knock-out mice. Nrf2 is a transcription 
factor keap-1 system that plays a role in the inflammation and evidence has shown that both 
peripheral and central inflammation plays a crucial role in the pathophysiology of depression 
[119]. The administration of diet rich in sulforaphane and glucorophanin prevented the depres-
sive-like behavior during adulthood; further authors showed that dietary intake of SFN-rich 
food during juvenile stages and adolescence could confer stress resilience in adulthood [119].
Contrasting results have also been reported, for example, Balb/c mice received sulforaphane (50 
mg/kg) previous to the injection of lipopolysaccharide afterward sickness behavior (an animal 
model of depression), and the proinflammatory response was evaluated in the hippocampus. 
The authors reported that sulforaphane administration prevented the induction of pro-inflam-
matory mediators (IL-b; IL-6, Cybb, INOS) but did not improve sickness behavior [120, 121]. 
Therefore, the use of sulforaphane to prevent depression-like behavior is inconclusive.
As far as we know, there is no information about the use of sulforaphane or glucorophanin in 
animal models of menopause. However, it has been suggested that the advantage of broccoli 
consumption is that some phytochemicals promote the conversion of 16-a-hydroxyestrone 
to 2-hydroxyestrone, the first is a carcinogenic metabolite that has been linked to breast can-
cer risk whereas the latter product does not exhibit estrogenic properties in breast tissue. 
Apparently, the ingestion of broccoli sprouts could be a good strategy for the treatment of 
menopause symptoms [2, 122, 123].
In our laboratory, several doses (0.1, 1.0, 10 mg/kg, i.p) of an extract of broccoli were evaluated 
for its anxiolytic and antidepressant-like effects after 7 days of administration to 3-week post-
ovariectomized rats. The results indicated an anxiolytic—but not antidepressant-like effect 
(Figure 5, unpublished results). The phytochemical involved in this action is unknown and 
studies to reveal it are running.
The fact that sulforaphane exerts anti-inflammatory properties and that according to the aeti-
ology of depression, the inflammatory process plays a major role in its aetiology, the con-
sumption of food or nutraceuticals with sulforaphane could be suitable.
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6. Comorbidity in menopause and alternative medicine
Fibromyalgia (FM) is a chronic, generalized pain syndrome that affects the musculoskeletal 
system [124]. It is characterized not only by a widespread pain observed due to the presence 
of multiple tender points but also by depressive behavior, fatigue and sleep disturbances 
without any structural or inflammatory cause [125, 126]. Studies have consistently demon-
strated a female predominance of this disease [127] with a major frequency in pre- and post-
menopause condition supporting that an abrupt decline or a reduced time of exposure to 
ovarian hormones may contribute to FM [128].
Although FM is not an inflammatory disease, it is known that a neuroinflammation process 
can occur, which is described as an increase in the production of interleukins at the central 
Figure 5. Effect of several doses (0.1, 1.0, 10 and 100 mg/kg, i.p) of aqueous extract of broccoli (Brassica oleraceae L) in the 
elevated plus-maze (A) and the forced swimming test (B) after 7 days of treatment. Broccoli extract reduced the anxiety-
like behavior (A) but lacks antidepressant-like effect (B). Data are presented as mean ± SE of 10–12 ovariectomized rats 
per group. *p < 0.05 versus control group; +p < 0.05 versus 0.1 mg/kg, One way-ANOVA followed by Student-Newman 
Keuls test. Unpublished results.
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nervous system level, such as IL-1β, IL-6, IL-8, IL-10 and TNF-α, and not at the peripheral 
level [129]. To date, it has not been possible to establish whether their elevated levels are 
associated with the painful process in FM since these have also been observed in patients with 
depression and sleep disorders [130]. The neuroendocrine alterations observed are usually at 
the level of the hypothalamic-pituitary-adrenal axis where there is hyperactivation, and it has 
been related to deficient levels of hormones [131] that could be part of the reasons of a major 
frequency in menopause [128].
As it was mentioned, anthocyanidins belong to the flavonoid group of plant-derived chemi-
cals, which have been commonly used for the treatment of chronic diseases. One randomized 
clinic test was done to evaluate the efficacy of this compounds (40, 80 and 120 mg/day) in the 
treatment of FM compared with a placebo group. The evaluation had duration of 52 weeks 
with each treatment given for 12 weeks, preceded by a 4-week baseline period. Authors con-
clude that anthocyanidins showed small but significant benefits at a dosage of 80 mg/day in 
the treatment of primary FM, mainly in the sleep disturbance in the presence of minor adverse 
effects like indigestion or nausea [132].
Chronic fatigue syndrome is also comorbid linked to early menopause and FM since it 
involves the muscular, nervous, hormonal and immune systems; it is often misdiagnosed as 
depression [133]. Isoflavones (daidzein and genistein) were capable of reversing alterations 
like chronic fatigue syndrome in an experimental model in mice suggesting their protective 
effect in this neuroimmune-endocrine disease [134].
7. Concluding remarks
1. Clinical reports show inconsistent results about the use of phytoestrogens effectiveness to 
treat vasomotor and psychiatric disorders associated with menopause. The biotransforma-
tion by microbiota to deliver the main active compounds appears to be fundamental to 
observe positive effects.
2. Preclinical data show that the effect of phytoestrogens depends on the time of administra-
tion as well as the endocrine state of rats, suggesting that these factors could also contrib-
ute to explain the inconsistency between results observed in humans.
3. More studies are necessary to evaluate if the same phytoestrogen can induce both anxio-
lytic- and antidepressant-like action and if their effect depends on the endocrine state.
4. Clinical and preclinical studies indicated that the use of phytoestrogens is safe due to the 
high antioxidant activity. However, meta-analysis studies are inconclusive. Therefore, 
phytoestrogens as restitution therapy should be monitored.
5. Functional food and nutraceuticals are an important source of a wide variety of phytoestrogens.
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